LOTTE BIOLOGICS Secures Key Manufacturing Partnership with U.S. Biopharmaceutical Company

LOTTE BIOLOGICS Secures New Contract Manufacturing Partnership

LOTTE BIOLOGICS, led by CEO James Park, has made a promising announcement regarding a new contract manufacturing agreement with a prominent U.S.-based biopharmaceutical company. This partnership is noteworthy as it represents a late-stage to commercial collaboration, particularly focusing on a Phase 3 program that is set to expand into multiple new therapeutic indications.

The partnership will play an essential role in supplying medicines following regulatory approvals, thereby significantly impacting patient access to innovative treatments. The name of the partner is kept confidential due to existing obligations; however, it reflects the strong industry trust in LOTTE BIOLOGICS’ manufacturing competencies.

Since the beginning of the year, LOTTE BIOLOGICS has successfully secured three major contracts, underscoring its growing influence and competitive standing in the global biopharmaceutical landscape. This latest agreement reiterates the company's commitment to addressing the industry’s current trends, particularly reshoring and supply chain realignment that many biomanufacturers in the U.S. are adopting.

One of the standout features of LOTTE BIOLOGICS is its ability to leverage its dual-site operations in Syracuse, New York, and Songdo, Korea—both working under a unified quality system. This strategic setup not only enhances the company’s capability to respond flexibly to market demands but also ensures a reliable supply chain, crucial for its U.S.-based clients. By keeping close ties with key biopharma hubs, LOTTE BIOLOGICS is effectively broadening its global client base.

A representative from LOTTE BIOLOGICS expressed optimism about the partnership, stating, "This late-stage to commercial partnership demonstrates strong client confidence in our global network and technical expertise. We take pride in supporting our partner’s strategy for indication expansion and accelerating the availability of innovative therapies to patients worldwide."

This partnership highlights LOTTE BIOLOGICS’ robust commercial-scale manufacturing capabilities and quality leadership within the industry, particularly leveraging geographical advantages that its U.S. operations offer. The contract is said to extend through mid-2030, providing a solid foundation for future collaborative developments.

LOTTE BIOLOGICS is poised to play a pivotal role in the global biopharmaceutical sector by facilitating meaningful access to innovative medicines. As part of its strategic efforts, the company is excited about building a foundation for bold science and dependable delivery, benefiting patients globally.

In conclusion, the establishment of this partnership is a significant milestone for LOTTE BIOLOGICS, reflecting a robust trajectory of growth and innovation in an evolving industry landscape. With its eyes set firmly on the future, the company is prepared to navigate and respond to the dynamic needs within the biopharmaceutical sector.